Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Esbrient 267mg Tablet: Enhancing Pulmonary Function in Idiopathic Pulmonary Fibrosis
Introduction:
Esbrient 267mg Tablet is a vital prescription medication utilized in the management of idiopathic pulmonary fibrosis. It targets the reduction of scarring and swelling within the lungs, consequently improving respiratory function.
Key Information:
Type of Medication: Prescription Medicine
Indication: Treatment of Idiopathic Pulmonary Fibrosis
Uses:
Treatment of Idiopathic Pulmonary Fibrosis: Esbrient 267mg Tablet is specifically designed to address idiopathic pulmonary fibrosis, a condition characterized by the thickening and stiffening of lung tissue, leading to the formation of scar tissue within the lungs. This irreversible process often manifests as symptoms like shortness of breath or a persistent dry cough.
Benefits:
Enhanced Pulmonary Function: By mitigating scarring and fibrosis in the lungs, Esbrient 267mg Tablet facilitates improved breathing function. Patients may experience a reduction in symptoms such as shortness of breath, contributing to enhanced quality of life.
Mechanism of Action:
Antifibrotic Properties: Esbrient 267mg Tablet operates as an antifibrotic medication, targeting the reduction of fibrosis and swelling within the pulmonary tissues. By diminishing scarring and inflammation, it effectively alleviates breathing difficulties, making respiratory function more manageable.